With a median follow-up of 122 months ( IQR 73-185 ) , median progression-free survival was 80 months ( 95 % CI 65-93 ) in the cediranib group and 74 months ( 57-85 ) in the placebo group ( HR 093 , 80 % CI 074-119 , 95 % CI 065-135 ; p = 072 ) .